Postby roadrunner » Thu Jul 22, 2021 11:00 am
This is great to hear, and I doubt too many folks on here need a note of caution in this area. But perhaps it’ll be useful for someone. With respect to immune response to vaccines, including the wonderful mRNA vaccines, responses are very variable, so one person’s case is mostly relevant for that person, and not applicable to everybody. In this case, while the literature I’ve seen supports expectation of strong vaccine response in solid tumor patients, there are LOTS of variables. For example, antibody level indicators alone may not establish optimal or sufficient protection, protective levels of response may vary with the emergence of new variants (e.g., the currently dominant Delta variant, which is far more infectious than previous versions), will definitely vary by individual, may vary by type and stage of chemo, and may wane over time (or may not). We also won’t always see new, more vaccine-evasive variants until they are at least somewhat dispersed. In other words, this is a hopeful story, but I at least would urge continued caution in a community like this one until and unless vaccination levels increase in the general population (thus reducing community spread to lower levels).
7/19: RC: Staged IIIA, T2N1M0
approx 4.25 cm, low/mid rectum, mod. well diff.; lung micronodule
8/19-10/19 4 rds.FOLFOX neoadjuvant, 3 w/Oxiplatin (reduced 70-75%)
neoadjuvant chemorad 11/19
4 rounds FOLFOX July-August 2020
ncCR 10/20; biopsies neg
TAE 11/20, tumor cells removed
Chest CT 3/30/21 growth in 2 nodules (3 and 5mm)
VATS 12/8/21 sub-pleural met 7mm.
SBRT nodule 1/22
6/20/22 TAE rectal polyp benign)
NED from 3/22 - 3/23
4 cycles FOLFIRI
LUL VATS lobectomy for radio resistant met 7/7/23